Analysist's forecast Type 1 Diabetes Mellitus Therapeutics Market Will Grow at a CAGR of 7.9% by 2021

Type 1 Diabetes Mellitus (T1DM) is a chronic, progressive and serious disease characterized by a destruction or failure of insulin-secreting pancreatic beta cells, usually as a result of an autoimmune response. The resulting insulin deficiency prevents insulin-sensitive cells from carrying out essential glucose metabolism and leads to hyperglycemia (high blood glucose levels). As a result, immediate and lifelong treatment with exogenous insulin therapy is initiated upon diagnosis of T1DM. Exogenous insulin has remained the mainstay of T1DM therapy since it was used to treat the first human patient in 1922.

Get Sample Copy of Report with TOC@ http://www.marketresearchstore.com/report/type-1-diabetes-mellitus-therapeutics-in-major-developed-41102#RequestSample

Consequently, insulin products comprise the vast majority of the T1DM market, which is largely monopolized by three big pharma players: Eli Lilly, Novo Nordisk and Sanofi. However, insulin treatment regimens are often inconvenient and are associated with undesirable side effects such as hypoglycemia (low blood glucose levels) and weight gain. In addition, there is a significant unmet need for more diversified treatment options including therapies capable of altering the clinical course of the pathological beta cell destruction and adjuvant therapies capable of improving glycemic control and reducing insulin requirements.

Scope

The report assesses the current T1DM market and forecasts market trends to 2021. Areas covered include

An introduction to T1DM, which includes classification, symptoms, etiology, pathophysiology, co-morbidities and complications, diagnosis and treatment

An analysis of the leading insulin therapies in the current T1DM marketed products landscape.

An analysis of the pipeline for T1DM. This includes a breakdown of pipeline molecules by stage of development, molecule type, route of administration, molecular target and novelty. Trends in T1DM clinical trial size, duration and failure rates, by molecule type and molecular target are discussed. A comparative analysis of the most promising pipeline molecules is also provided.

Forecast projections for the T1DM market to 2021. An analysis is provided for the global market and each of the eight major markets. The forecast incorporates projected, low and high variance scenarios based on treatment usage patterns and annual therapy costs in each of the major markets.

An analysis of strategic consolidations, including co-development and licensing deals, within the T1DM indication.

Reasons to buy

The report will provide clients with a strong understanding of the T1DM indication and an appreciation of the evolving landscape of the T1DM therapeutics market. The report will enable clients to

Appreciate the current T1DM marketed products landscape, including the dominant therapeutic strategies, products, and companies, and recognize gaps within the market and areas of unmet need

Identify trends and developments within the T1DM pipeline and consider how the future competitive environment will be impacted.

Consider market opportunities and potential risks by examining trends in T1DM clinical trial duration and size, as well as clinical trial failure rates, amongst clinical phases and molecule types

Assess the potential clinical and commercial impact of current late-stage pipeline molecules on the T1DM therapeutics market

Understand how strategic consolidations have shaped the current T1DM pipeline and marketed products landscapes

Make an enquiry @ http://www.marketresearchstore.com/report/type-1-diabetes-mellitus-therapeutics-in-major-developed-41102#InquiryForBuying

Market Research Store is a single destination for all the industry, company and country reports. We feature large repository of latest industry reports, leading and niche company profiles, and market statistics released by reputed private publishers and public organizations.

Deerfield Beach, Florida 33442

This release was published on openPR.